Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fingernail clipping could spot diabetes risk

NCT ID NCT07039357

Diagnosis Sponsor: Glyconics Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 2 times

Summary

This study tests a new way to screen for type 2 diabetes by measuring sugar levels in fingernails. Researchers will compare results from 100 adults (half with known diabetes, half without) to standard blood tests. The goal is to see if this simple, non-invasive method can accurately identify people who may have diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Apparently healthy adults (≥18 years of age) with known (n=50) or unknown T2DM status (n=50) willing to participate in and provide a written consent for the study * willingness to undertake assisted assessment of glycaemia by both the NIR spectra measurement, and HbA1c by finger prick test * Individuals with at least one visually assessed undamaged, intact (preferably middle) fingernail Exclusion Criteria: * Individuals with any known medical conditions impacting the PoC device assessment methodology for glycaemia, such as * Severe forms of anaemia (diagnosed iron deficiency, sickle cell anaemia or similar) * haemoglobinopathies or atypical haemoglobin subtypes not detectable by the assay * severe renal impairment (CKD stage III-IV) or decompensated hepatic disease * severe Vitamin D deficiency (diagnosed or measured 25(OH)D3 \< 25 nmol/ml) * known severe immunodeficiency such as HIV, malignancy or other chronic condition significantly impacting assessment of glycaemia * eating disorders (as per clinical assessment) * recent (within 28 days) blood donation * known / diagnosed other diabetes such as T1DM, GDM, MODY, etc. * For the Glyconics-DS device / targeted nail: * Mechanical damage or marks on the surface of the nail after removal of nail polish, or * Use of acrylic or gel nail decoration and polish, which cannot be removed.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus Healthy

Contacts and locations

Locations

  • Barts Liver Centre

    London, United Kingdom

  • Tameside and Glossop Integrated Care NHS Foundation Trust, Tameside General Hospital, Fountain Street

    Ashton-under-Lyne, England, OL6 9RW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.